ZBIO Quote, Financials, Valuation and Earnings

Rigel Pharmaceuticals, Inc. has a net margin of -335.73% compared to Zenas BioPharma, Inc.'s net margin of 40.17%. Zenas BioPharma, Inc.'s return on equity of -68.2% beat Rigel Pharmaceuticals, Inc.'s return on equity of 273.99%.

Zenas BioPharma, Inc. has a consensus price target of $47.75, signalling upside risk potential of 46.52%. On the other hand Rigel Pharmaceuticals, Inc. has an analysts' consensus of $49.60 which suggests that it could grow by 16.76%. Given that Zenas BioPharma, Inc. has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Zenas BioPharma, Inc. is more attractive than Rigel Pharmaceuticals, Inc..

Zenas BioPharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Rigel Pharmaceuticals, Inc. has a beta of 1.110, suggesting its more volatile than the S&P 500 by 11.026%.

Zenas BioPharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zenas BioPharma, Inc. pays -- of its earnings as a dividend. Rigel Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Zenas BioPharma, Inc. quarterly revenues are --, which are smaller than Rigel Pharmaceuticals, Inc. quarterly revenues of $69.5M. Zenas BioPharma, Inc.'s net income of -$51.5M is lower than Rigel Pharmaceuticals, Inc.'s net income of $27.9M. Notably, Zenas BioPharma, Inc.'s price-to-earnings ratio is -- while Rigel Pharmaceuticals, Inc.'s PE ratio is 6.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zenas BioPharma, Inc. is 91.05x versus 2.77x for Rigel Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Royalty Pharma Plc has a net margin of -335.73% compared to Zenas BioPharma, Inc.'s net margin of 72.91%. Zenas BioPharma, Inc.'s return on equity of -68.2% beat Royalty Pharma Plc's return on equity of 13.15%.

Zenas BioPharma, Inc. has a consensus price target of $47.75, signalling upside risk potential of 46.52%. On the other hand Royalty Pharma Plc has an analysts' consensus of $46.32 which suggests that it could grow by 20.21%. Given that Zenas BioPharma, Inc. has higher upside potential than Royalty Pharma Plc, analysts believe Zenas BioPharma, Inc. is more attractive than Royalty Pharma Plc.

Zenas BioPharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Royalty Pharma Plc has a beta of 0.466, suggesting its less volatile than the S&P 500 by 53.41%.

Zenas BioPharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Royalty Pharma Plc offers a yield of 2.28% to investors and pays a quarterly dividend of $0.22 per share. Zenas BioPharma, Inc. pays -- of its earnings as a dividend. Royalty Pharma Plc pays out 43.94% of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zenas BioPharma, Inc. quarterly revenues are --, which are smaller than Royalty Pharma Plc quarterly revenues of $609.3M. Zenas BioPharma, Inc.'s net income of -$51.5M is lower than Royalty Pharma Plc's net income of $444.2M. Notably, Zenas BioPharma, Inc.'s price-to-earnings ratio is -- while Royalty Pharma Plc's PE ratio is 22.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zenas BioPharma, Inc. is 91.05x versus 9.38x for Royalty Pharma Plc. Usually stocks with elevated PS ratios are considered overvalued.

Viridian Therapeutics, Inc. has a net margin of -335.73% compared to Zenas BioPharma, Inc.'s net margin of -49.03%. Zenas BioPharma, Inc.'s return on equity of -68.2% beat Viridian Therapeutics, Inc.'s return on equity of -47.79%.

Zenas BioPharma, Inc. has a consensus price target of $47.75, signalling upside risk potential of 46.52%. On the other hand Viridian Therapeutics, Inc. has an analysts' consensus of $40.13 which suggests that it could grow by 21.48%. Given that Zenas BioPharma, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Zenas BioPharma, Inc. is more attractive than Viridian Therapeutics, Inc..

Zenas BioPharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Viridian Therapeutics, Inc. has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.612%.

Zenas BioPharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viridian Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zenas BioPharma, Inc. pays -- of its earnings as a dividend. Viridian Therapeutics, Inc. pays out -- of its earnings as a dividend.

Zenas BioPharma, Inc. quarterly revenues are --, which are smaller than Viridian Therapeutics, Inc. quarterly revenues of $70.6M. Zenas BioPharma, Inc.'s net income of -$51.5M is lower than Viridian Therapeutics, Inc.'s net income of -$34.6M. Notably, Zenas BioPharma, Inc.'s price-to-earnings ratio is -- while Viridian Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zenas BioPharma, Inc. is 91.05x versus 37.88x for Viridian Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XOMA Royalty Corp. has a net margin of -335.73% compared to Zenas BioPharma, Inc.'s net margin of 52.48%. Zenas BioPharma, Inc.'s return on equity of -68.2% beat XOMA Royalty Corp.'s return on equity of 17.31%.

Zenas BioPharma, Inc. has a consensus price target of $47.75, signalling upside risk potential of 46.52%. On the other hand XOMA Royalty Corp. has an analysts' consensus of $64.50 which suggests that it could grow by 153.04%. Given that XOMA Royalty Corp. has higher upside potential than Zenas BioPharma, Inc., analysts believe XOMA Royalty Corp. is more attractive than Zenas BioPharma, Inc..

Zenas BioPharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison XOMA Royalty Corp. has a beta of 0.941, suggesting its less volatile than the S&P 500 by 5.919%.

Zenas BioPharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XOMA Royalty Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.54 per share. Zenas BioPharma, Inc. pays -- of its earnings as a dividend. XOMA Royalty Corp. pays out 39.59% of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zenas BioPharma, Inc. quarterly revenues are --, which are smaller than XOMA Royalty Corp. quarterly revenues of $9.4M. Zenas BioPharma, Inc.'s net income of -$51.5M is lower than XOMA Royalty Corp.'s net income of $10.3M. Notably, Zenas BioPharma, Inc.'s price-to-earnings ratio is -- while XOMA Royalty Corp.'s PE ratio is 34.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zenas BioPharma, Inc. is 91.05x versus 8.87x for XOMA Royalty Corp.. Usually stocks with elevated PS ratios are considered overvalued.